{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:25:22Z","timestamp":1761582322423},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,8,15]]},"DOI":"10.2169\/internalmedicine.2900-23","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T22:10:59Z","timestamp":1704147059000},"page":"2283-2287","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Efficacy of Imdevimab\/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies"],"prefix":"10.2169","volume":"63","author":[{"given":"Masao","family":"Hagihara","sequence":"first","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihiro","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Sakai-Tagawa","sequence":"additional","affiliation":[{"name":"Division of Virology, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutsumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Virology, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiya","family":"Yamayoshi","sequence":"additional","affiliation":[{"name":"Division of Virology, Institute of Medical Science, The University of Tokyo, Japan"},{"name":"The Research Center for Global Viral Disease, Research Institute, National Center for Global Health and Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoko","family":"Iwatsuki-Horimoto","sequence":"additional","affiliation":[{"name":"Division of Virology, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[{"name":"Division of Virology, Institute of Medical Science, The University of Tokyo, Japan"},{"name":"The Research Center for Global Viral Disease, Research Institute, National Center for Global Health and Medicine, Japan"},{"name":"Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Japan"},{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv 4: 5966-5975, 2020.","DOI":"10.1182\/bloodadvances.2020003170"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 7: e737-e745, 2020.","DOI":"10.1016\/S2352-3026(20)30251-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ohara S, Fujii T, Ide S, Uchida T, Inoue M, Hagaihara M. Clinical characteristics and risk factors associated with nosocomial COVID-19 infection in patients with hematological disorders in Japan. Int J Hematol 114: 719-724, 2021.","DOI":"10.1007\/s12185-021-03172-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Passamonti F, Romano A, Salvini M, et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br J Haematol 195: 371-377, 2021.","DOI":"10.1111\/bjh.17704"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Narita K, Nakaji S, Tabata R, et al. Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol 115: 728-736, 2022.","DOI":"10.1007\/s12185-022-03305-z"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mittelman M, Magen O, Barda N, et al. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood 139: 1439-1451, 2022.","DOI":"10.1182\/blood.2021013768"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fujii T, Hagihara M, Mitamura K, et al. Anti-SARS CoV-2 IgG in COVID-19 patients with hematological diseases: a single-center, retrospective study in Japan. Intern Med 61: 1681-1686, 2022.","DOI":"10.2169\/internalmedicine.9209-21"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hagihara M, Imai Y, Uchida T, et al. Successful elimination of SARS-CoV-2 following vaccination with BNT162b2 after prolonged viral infection in an immunocompromised lymphoma patient. Intern Med 61: 2215-2219, 2022.","DOI":"10.2169\/internalmedicine.9513-22"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 183: 1901-1912 e9, 2020.","DOI":"10.1016\/j.cell.2020.10.049"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk 20: 774-776, 2020.","DOI":"10.1016\/j.clml.2020.08.017"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med 387: 468-470, 2022.","DOI":"10.1056\/NEJMc2207519"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wada D, Nakamori Y, Maruyama S, et al. Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection. Exp Hematol Oncol 11: 53, 2022.","DOI":"10.1186\/s40164-022-00307-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shimizu A, Shirai I, Ogawa K, et al. Persistent SARS-CoV-2 infection in a patient with nephrotic syndrome under rituximab therapy: successful treatment with a combination of remdesivir and monoclonal antibodies. Intern Med 61: 3703-3708, 2022.","DOI":"10.2169\/internalmedicine.0241-22"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mikulska M, Sepulcri C, Dentone C, et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis 77: 280-286, 2023.","DOI":"10.1093\/cid\/ciad181"},{"key":"15","unstructured":"15. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med 385: e81, 2021."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 384: 238-251, 2021.","DOI":"10.1056\/NEJMoa2035002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Razonable RR, Pawlowski C, O'Horo JC, et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine 40: 101102, 2021.","DOI":"10.1016\/j.eclinm.2021.101102"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Liu EC, Lee JH, Loo A, et al. Casirivimab-Imdevimab (REGN-COV2) for mild to moderate SARS-CoV-2 infection in kidney transplant recipients. Kidney Int Rep 6: 2900-2902, 2021.","DOI":"10.1016\/j.ekir.2021.08.032"},{"key":"19","unstructured":"19. Group RC. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399: 665-676, 2022."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol 32: e2381, 2022.","DOI":"10.1002\/rmv.2381"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Brown LK, Moran E, Goodman A, et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol 149: 557-561 e1, 2022.","DOI":"10.1016\/j.jaci.2021.10.031"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med 2022.","DOI":"10.1101\/2022.08.12.22278699"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Wu MY, Shepherd STC, Fendler A, et al. Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer. Cancer Cell 41: 821-823, 2023.","DOI":"10.1016\/j.ccell.2023.04.005"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/16\/63_2900-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T03:28:56Z","timestamp":1723865336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/16\/63_2900-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":23,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2900-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"article-number":"2900-23"}}